3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
2
Other solid neoplasm
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Wilms Tumor
1
Solid Tumors
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Retinoblastoma
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Malignant Solid Tumors
1
Hepatoblastoma
1
Carcinoma, Renal Cell
1
Interventions
Cyclophosphamide
6
Thiotepa
5
Granulocyte Colony-Stimulating Factor
4
Filgrastim
4
Etoposide
4
Cisplatin
4
Busulfan
4
tislelizumab
3
Melphalan
3
Carboplatin
3
tazemetostat
2
regorafenib
2
pembrolizumab
2
belinostat
2
Topotecan
2
Temozolomide
2
Radiotherapy
2
Peripheral Blood Stem Cell Transplantation
2
Mesna
2
Ifosfamide
2
Doxorubicin
2
spartalizumab
1
sodium thiosulfate
1
sargramostim
1
pegylated granulocyte colony-stimulating factor
1
fludarabine phosphate
1
fludarabine
1
etoposide phosphate
1
entinostat
1
cixutumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
pegylated granulocyte colony-stimulating factor
×
Other solid neoplasm
×
Clear all
NCT02390843
2020-04-03
AflacST1402
Emory University
Phase 1
Completed
13 enrolled